Zika virus (ZIKV) infection is a well-nurtured topic for healthcare personnel nowadays.
| INTRODUCTION

Zika virus (ZIKV) is a member of the virus family Flaviviridae, genus
Flavivirus. It is a 40-nm virus and has icosahedral symmetry. ZIKV has a non-segmented, single-stranded, positive sense RNA genome. The virus is transmitted by mosquitoes from the genus Aedes, most commonly Aedes aegypti. Zika virus infection has become a global health issue nowadays.
1 Table 1 tells us about the history of the spread of this infection all over the world. 1, 2 Prediction says that there will be 4 million ZIKV-infected patients in 2016. In February 2016, case of sexually transmitted ZIKV has been reported from Texas. In this very month, World
Health Organization has declared ZIKV to be a "Public Health
Emergency of International Concern." The extent of spread of this infection has stolen the attention of healthcare providers. Now the interesting fact is that up to 80% of the cases are asymptomatic.
But several complications of this infection have also been noted.
Particularly the effects on the fetuses of affected mothers are a great concern. 3 
| CLINICAL MANIFESTATIONS
After a mosquito bite, the first symptoms of ZIKV usually develop Thrombocytopenia, palatal petechiae, and uveitis have been reported.
Irritability, walking with a limp, difficulty moving an extremity may be presenting symptoms in infants and young children. There may be pain on palpation, or pain with active or passive movement of the affected joint in them. 4 In this article, we have particularly emphasized over the effects on pregnant ladies as well as newborn children.
| DIAGNOSIS
For adults who have presented within 7 days after onset of symptoms, The centers for disease control and prevention (CDC) has suggested obtaining at least three full thickness placental samples from the middle third of placental disk as well as at least one from the placental disk margin (5 x 12 cm strip of the fetal membranes) and at least four segments of 2.5 cm from the umbilical cord. Fetal tissue testing is also warranted for fetal losses in women with a history of ZIKV exposure.
5
CDC has guidelines for the definite diagnosis of ZIKV infection in pregnant women. It is described in Figures 1, 2 , and 3. in the first trimester is found to be at an increased risk of developing congenital malformations. 9 Another important point is that all symptomatic pregnant women should undergo tests for ZIKV, CHIKV, and DENV, even if ZIKV has already been detected, because these have a clinical resemblance and they may have additive effects on the fetus. 
| MODES OF TRANSMISSION TO THE FETUS
Besnard et al., in 2014 had not found supportive data regarding the transplacental transmission of ZIKV from mother to the fetus. They 
| EFFECTS ON FETUS
Microcephaly (usually head circumference below 3 SD of the mean) is the most striking finding in the fetuses of affected mothers by ZIKV.
Clinically the affected infants presented with irritability, hyper-reflexia, hypertonia or spasticity, tremors, and seizures. 15 Other anomalies are described in Table 2 . and fronto-occipital diameters below the third percentile were taken as microcephaly. Seven cases were found to be microcephaly. MRI was performed in five cases. Zika virus was positive in three of these five cases. 30 Another study indicates that early pregnancy infection may result in a long viral shedding and severe brain malformations. But the problem may be detectable only later in pregnancy. Here, CT examination was performed at 30 days of life with 3D post-processing. A 3D physical model from the CT data has been obtained, and it has been printed onto thermoplastic acrylonitrile butadiene styrene. This model displayed various CNS anomalies. Neuroimaging findings by MRI at 1 month of age were also helpful to detect the abnormalities. 31 
| MANAGEMENT FOR PREGNANT LADIES
There is no specific treatment for ZIKV except rest and symptomatic management. Anyone living in or traveling to the ZIKV-infected area are at risk of being affected. Naturally, pregnant women are not exceptions. Use of long sleeve dress, mosquito repellants, elimination of stagnant water near household is age-old and very effective methods. 28 Delaying pregnancy for more than 6 months has been shown to be useful for reduction of prenatal exposure of ZIKV. The delay should be initiated early in an outbreak. 32 Seasonal planning for conception depending upon the epidemiological data of a particular area is also necessary. 33 The Food and Drug Administration (FDA) recommended deferral of blood donors in affected U.S. areas. The safety of blood products will be detected by FDA-approved pathogen reduction technology (PRT). FDA has recommended that whole blood and blood components for transfusion be obtained from U.S. areas with no active ZIKV infection. 34 Apart from these, there are specific guidelines for pregnant ladies. The https://www.gov.uk/guidance/ zika-virus website has provided the guideline for pregnant women. This guideline has been described in brief in Figure 4 .
35
CDC has recommendations for the safety of pregnant ladies as well as of fetuses. These are the following:
The UK guideline for pregnant women regarding ZIKV infection 1. Pregnant women should avoid travel to an area with active Zika virus transmission.
2.
If a pregnant woman has to travel to one of these areas, she should consult her healthcare provider.
3.
If she travels, she should be cautious to avoid mosquito bites. She should also be counseled for the prevention of sexual transmission during the trip.
4.
Pregnant woman with a partner, who lives in or has travelled to an area with Zika, should use condoms or other barrier methods every time she has sex (up to 28 days after his return if he did not develop ZIKV symptoms, either while abroad or within 2 weeks of his leaving the affected country or for 6 months following recovery if he had ZIKV symptoms during that period).
5.
Preferably she should not have sex (vaginal, anal and oral sex, and the sharing of sex toys) with that partner for the duration of her pregnancy. As mentioned previously, the combination of neuroprotective and antiviral molecules are emerging as anti-ZIKV agents. 34 Recently, Emricasan, a pan-caspase inhibitor, has been shown to protect human neural progenitor cells in organoid cultures. Anthelmintic niclosamide has also been found to inhibit ZIKV replication. Cyclin-dependent kinase inhibitor Seliciclib (PHA-690509) has also shown promise.
| ONGOING RESEARCH AND FUTURE ASPECTS
Adequate safety data of these drugs for pregnant mothers are yet to come. 37 
| CONCLUSION
The impact of ZIKV infection on pregnant ladies and their newborns are serious. But still, there are many unknown facts. The exact percentage of mothers at risk of having the infection and the highrisk time of gestation to acquire the infection are still not answered.
The relation of neonatal abnormality with the time of acquiring infection is still to be cleared. The emerging treatment and vaccines are yet to prove their safety on pregnant mothers. But undoubtedly we should be cautious to avoid infection in pregnant mothers.
If they got infected, timely monitoring fetus by imaging is necessary.
Proper counseling of the mothers is necessary for the prevention of unnecessary panic. Hopefully, more data will come in the future so that more preventive measures can be taken. For healthy future of the society, it is important to combat this problem with all possible ways.
